Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda

Newton, Robert; Ziegler, John L.; Bourboulia, Dimitra; Casabonne, Delphine; Beral, Valerie; Mbidde, Edward; Carpenter, Lucy; Parkin, Donald Maxwell; Wabinga, Henry; Mbulaiteye, Sam M.; Jaffe, Harold W.; Weiss, Robin A.; Boshoff, Chris

doi:10.1038/sj.bjc.6601113

Cited by 31 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Screening transplant recipients and blood donors for HHV-8 infection may be desirable. It may be also be good to evaluate donors for HHV-8 [105,106]. In addition, use of highly active anti-retroviral therapy (HAART) substantially reduces the risk of developing new KS.…”

Section: Therapymentioning

confidence: 98%

Kaposi's sarcoma: An update

Schwartz

2004

Journal of Surgical Oncology

128

114

View full text Add to dashboard Cite

While there have been many important advances in the study of Kaposi's sarcoma (KS), it remains both a challenge and an enigma in many ways. Kaposi's original description of "multiple idiopathic hemorrhagic sarcoma[s]" in patients who died within 2-3 years resembles KS in AIDS more than classic KS in elderly men of Italian, Jewish, or Mediterranean lineage, in whom the disease is usually benign. KS had been evident in about one-third of those with early AIDS, often as its presenting sign, a pattern markedly reduced in recent times since the introduction of highly active anti-retroviral therapy (HAART). The most important advance has been the convincing etiologic linkage of KS with human herpesvirus 8 (HHV-8), which is necessary but not sufficient. It has a low prevalence in the general population of the USA and UK, with an intermediate rate in Italy and Greece, and a high one in Uganda. KS risk may be significantly lower in AIDS patients with a history of anti-herpes therapy. Many aspects of HHV-8, including its transmission pattern and different genospecies, are being scrutinized. The diagnosis of KS may be difficult. One should be aware of KS clinical variants, including telangiectatic, eccymotic, and keloidal KS. One must consider a number of other disorders, including bacillary angiomatosis. HHV-8 DNA sequences in dermatofibromas and other tumors should probably not be viewed as representing a marker for KS. Therapeutic options vary for KS. Intralesional and low-dose outpatient intravenous vinblastine may be valuable, as immunosuppression with KS is not a good idea if it can be avoided. Anti-herpes virus therapy may have potential for wide use, especially in preventing the development of KS in at risk populations, such as HHV-8 seropositive individuals undergoing transplantation surgery.

show abstract

Section: Therapymentioning

confidence: 98%

Kaposi's sarcoma: An update

Schwartz

2004

Journal of Surgical Oncology

128

114

View full text Add to dashboard Cite

show abstract

“…It may be also be of value to evaluate donors for HHV-8. 145,354,355 Furthermore, the use of sirolimus or its analogues rather than calcineurin inhibitors may reduce the incidence of KS in transplant recipients. 331 Employing HAART significantly reduces the risk of developing new cases of KS.…”

Section: Preventionmentioning

confidence: 99%

Kaposi sarcoma: A continuing conundrum

Schwartz

Micali

Nasca

et al. 2008

Journal of the American Academy of Dermatology

203

212

View full text Add to dashboard Cite

“…Concerning the African continent, most of the studies on HHV-8 viral markers in KS patients have been performed in East and South African areas, especially in Zimbabwe (6-8), Uganda (21), and South African Republic (25,26). Very few data on such viral markers in KS patients from West (1) and Central African countries exist.…”

mentioning

confidence: 99%

Human Herpesvirus 8 Serological Markers and Viral Load in Patients with AIDS-Associated Kaposi's Sarcoma in Central African Republic

et al. 2005

View full text Add to dashboard Cite

Epidemic Kaposi's sarcoma (KS) is one of the most frequent types of cancer in several African countries; however, very few data are available on human herpesvirus 8 (HHV-8) markers in KS patients from Central Africa. In a series of 36 AIDS-KS cases from Central African Republic, we showed, using a real-time PCR quantitative assay, the high frequency (82%) of detectable HHV-8 DNA in peripheral blood mononuclear cells (PBMCs). We also found that the level of antibodies directed against lytic or latent HHV-8 antigens is not correlated to the amount of HHV-8 viral load in the PBMCs, and finally, we demonstrated a much higher viral load in tumoral skin lesions (6.07 log copies/g DNA) than in unaffected skin (2.93 log copies/g DNA) or in PBMCs (2.55 log copies/g DNA).

show abstract

Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda

Cited by 31 publications

References 9 publications

Kaposi's sarcoma: An update

Kaposi's sarcoma: An update

Kaposi sarcoma: A continuing conundrum

Human Herpesvirus 8 Serological Markers and Viral Load in Patients with AIDS-Associated Kaposi's Sarcoma in Central African Republic

Contact Info

Product

Resources

About